News | August 01, 2023
Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
This product would be manufactured at Lupin's Nagpur facility in India
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Moist wound dressing for chronic wound treatment now available in Germany
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Subscribe To Our Newsletter & Stay Updated
